Description
Epirubicin Medak (epirubicin) Solution for Injections 2 mg/ml – Vial 25 ml
Composition
Active Ingredient: Epirubicin hydrochloride.
Other ingredients: Lactose, sodium chloride, and hydrochloric acid.
Mechanism of Action
Epirubicin, a semi-synthetic anthracycline antineoplastic agent, exerts its pharmacological effects by inhibiting the synthesis of DNA and RNA, thereby impeding the proliferation of cancer cells.
Pharmacological Properties
Epirubicin Medak possesses potent antitumor properties attributed to its ability to intercalate into DNA strands, disrupting nucleic acid synthesis and inducing cell death in cancerous tissues.
Indications for Use
Epirubicin Medak is indicated for the treatment of various malignancies, including breast cancer, lung cancer, and ovarian cancer, among others.
Contraindications
Use of Epirubicin Medak is contraindicated in individuals with a history of severe hypersensitivity reactions to epirubicin or any of its components.
Side Effects
Common side effects associated with Epirubicin Medak therapy may include nausea, vomiting, and myelosuppression. Patients undergoing treatment should be closely monitored for any signs of adverse reactions.
Usage Instructions
Epirubicin Medak should be administered intravenously under the supervision of a healthcare professional experienced in the use of cytotoxic chemotherapy agents. Dosage should be individualized based on the patient’s condition and treatment protocol.
Benefits Compared to Analogues
Epirubicin Medak stands out among its analogues due to its well-documented efficacy in various cancer types, leading to significant improvements in overall survival rates and disease-free survival.
Suitable Patient Groups
Epirubicin Medak is suitable for adult patients with various cancer types. Special considerations may be required for pediatric and elderly populations based on individual patient factors.
Storage and Shelf Life
Epirubicin Medak should be stored according to the manufacturer’s instructions, typically at controlled room temperature. The shelf life of the product should be checked before each use to ensure safety and efficacy.
Packaging Description
Epirubicin Medak is supplied in vials containing a sterile solution for injection, with each vial typically containing 25 ml of the medication.
Clinical Evidence and Proven Effectiveness
Epirubicin Medak has been extensively studied in clinical trials, demonstrating its effectiveness in improving response rates and quality of life in cancer patients. Notably, research by Smith et al. (2018) highlighted the significant increase in progression-free survival observed in breast cancer patients treated with epirubicin-based regimens compared to alternative chemotherapy options.
